Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016–2020
Denis Piérard(Vrije Universiteit Brussel), Francis F. Arhin(Pfizer (United States))
Cited by 11
Related Papers
Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial
|The Lancet Infectious Diseases|2024|98
In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy
|International Journal of Antimicrobial Agents|2010|76
<i>In Vitro</i> Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam
|Antimicrobial Agents and Chemotherapy|2018|44
Hemolytic uremic syndrome in Belgium: incidence and association with verocytotoxin-producing Eschevichia coli infection
|Clinical Microbiology and Infection|1999|33